Skip to main content

News

Serotonin May Provide a Clue to SUDEP

Last Updated:

New research published by the American Academy of Neurology in the latest issue of the Neurology Journal has linked the brain chemical serotonin with a lower risk of seizure-related breathing problems.

The research was led by Dr. Samden Lhatoo of the University of Texas.

Epidyolex receives marketing approval by European Commission

Last Updated:

Further to our recent news article on this matter, we can confirm that CBD based drug Epidyolex has received marketing approval by the EU commission.

Approval for the drug has been granted for in Lennox Gastaut & Dravet Syndromes in patients over two years old who are already prescribed Clobazam (Frisium). The marketing approval will apply to all EU member states, including Ireland.

Meta-Analysis Study points to higher success rate for early surgical intervention

Last Updated:

A meta-analysis of studies regarding epilepsy surgery has concluded that the earlier surgical intervention takes place, the more chance a person has of becoming seizure- free.

The analysis was conducted by researchers from the Sahlgrenska Academy of the University of Gothenburg in conjunction with the Swedish Council for Assessment of Health Technology.

Their findings were recently published in the renowned journal, Neurology, from the American Academy of Neurology.

New research identifies membrane protein which can cause epilepsy

Last Updated:

New research from the Korea Brain Institute has identified the structure and mechanism of a membrane protein which can cause epilepsy.

Membrane proteins are the gatekeepers to the cell and are essential to the function of all cells. They control the flow of information or messages between cells.

Epidyolex turned down for NHS reimbursement

Last Updated:

The UK’s National Institute for Health and Care Excellence (NICE) has announced that it would not recommend Epidyolex (cannabidiol) combined with clobazam (Frisium) for the treatment of Lennox-Gastaut syndrome and Dravet syndrome.

Children with Epilepsy due to Genetic Abnormality respond better to Ketogenic Diet- American Research finds

Last Updated:

New research from the Ann & Robert H Lurie Children’s Hospital of Chicago has found that young children with epilepsy caused by genetic abnormality had a better response to the ketogenic diet compared to children with other types of epilepsy.

The ketogenic diet is a low carbohydrate, high fat diet that is used to treat epilepsy which has not responded to other treatments. More information on this can be found here.

CBD-based drug moves closer to authorisation in Europe

Last Updated:

The Human Medicines Committee of the European Medicines Agency have recently granted a positive opinion regarding the use of cannabidiol (CBD) based drug Epidyolex (spelled as Epidiolex in the US) in two forms of epilepsy.

As part of their July meeting, the committee recommended marketing approval for the drug in Lennox Gastaut & Dravet Syndromes in patients over two years old who are already prescribed Clobazam (Frisium).